Myasthenia Gravis Treatment Market
Segments - by Treatments (Medication, Surgery, and Others), End-Users (Hospitals, Clinics, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global myasthenia gravis treatment market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing adoption of rare diseases, approvals for promising drugs, increasing adoption of immunotherapies, and emergence of biologics.
Myasthenia gravis (MG) is rare, chronic, and progressive neuromuscular disorder which causes weakness of the head, eye, limb, respiratory muscles, and spinal. MG is autoimmune disorder in which against the acetylcholine receptor (AchR) antibodies are produced. Myasthenia gravis hampers the normal transmission of electrical signals from nerves to muscles.
According to the National Organization for Rare Disorders (NORD), approximately 20-35 per 100,000 individuals suffer from myasthenia gravis in the U.S. also, number of disorders are increasing over the last several decades. This is attributed to rising incidence of autoimmune disorders and better identification of patients across the globe.
Myasthenia gravis occurs generally in females than in males. Symptoms of MG appears at any age, but in men it’s appear during their 50s or 60s and in women usually in their 20s or 30s. There is no permanent cure for myasthenia gravis disease. But there are some treatments such as medications and surgery for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications. Currently, researchers are majorly focused on understanding the specifics of the autoimmune problems related to MG and improving diagnosis methods and treatments. Moreover, other important area of research physiology of the neuromuscular junction (NMJ), is improving its function irrespective of probable immune system attacks.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing research and development activities and growing number of clinical trials for treatment are anticipated to drive the market growth over the forecast period.
- Rising population with MG disease in emerging countries, growing geriatric population, and increasing cases of neuromuscular disorders are expected to boost the growth of the market.
- Increasing awareness about the treatment line among patients and growing number of clinical facilities are projected to propel the market growth.
- Side effects of drugs, high cost of treatment, and high dose combination results into severe muscle cramps are major factors that can impede the market growth.
- In Covid-19 pandemic situation researchers are focusing on Covid-19 research. Due to this other clinical trials and researches are reduced which hampered the growth of myasthenia gravis treatment market.
Scope of the Report
The report on the global myasthenia gravis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Myasthenia Gravis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Treatments (Medication, Surgery, and Others), End-Users (Hospitals, Clinics, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc. |
Market Segment Insights
Medication segment is projected to hold a key market share
Based on treatments, the myasthenia gravis treatment market is divided into medication, surgery, and others. The medication segment is expected to hold a key share of the market during the forecast period. This is due to medications are dramatically constrain the immune system and majorly manages the associated symptoms. Medications include immunotherapies such as corticosteroids, Soliris (eculizumab), and immunosuppressive drugs includes Neoral/Sandimmune (cyclosporine) and Prograf (tacrolimus).
Surgery is other major treatment alternative which includes a thymectomy (thymus removal). It is invasive in nature. The thymus deteriorates with age (thymic involution), though complete loss of the thymus in a significant manner is expected to weaken a patient’s immune system.
Increasing number of pipeline R&D of drug development is projected to fuel the growth of the myasthenia gravis treatment market. Recently, the U.S. FDA and the European Commission, approved Alexion Pharmaceuticals’ Soliris (eculizumab) for treating adult myasthenia gravis patients who are anti-AchR antibody-positive. Soliris is a complement and first inhibitor for this disorder. The rising use of immunosuppressant and monoclonal antibodies is targeted the reduction of lifelong exposure to corticosteroids.
Clinic segment is expected to expand at a rapid pace
On the basis of end-users, the myasthenia gravis treatment market is segmented into hospitals, clinics, and others. The hospital segment is expected to hold a key share of the market during the forecast period. The growth of the segment is attributed to high demand of advanced equipment for myasthenia gravis treatment and huge patient pool. Number of patient visits for the MG treatment is increasing because of accessibility of such facilities. Moreover, rising investment in state-of-the-art healthcare infrastructures is one of the major driving factor.
On the other hand, the clinic segment is anticipated to expand at a rapid pace during the forecast period. Recently, need of specialized treatments is increasing also many patients are choosing specialty clinics for effective treatment and quick diagnosis. Furthermore, many end-users are dependent on e-commerce channel for treatment. Such segments are majorly boosting the growth of myasthenia gravis treatment market.
North America is anticipated to dominate the market
On the basis of regions, the myasthenia gravis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America hold largest market share and is expected to exhibit a rapid growth rate in the coming years. The regional market growth can be attributed to growing expenditure on healthcare, huge adoption of immunotherapies and monoclonal antibodies, favorable reimbursement scenario, and presence of established R&D facilities.
However, the market of Asia Pacific is anticipated to expand at an impressive CAGR during the forecast period owing to the growing generation of revenue through medications such as immunosuppressant and monoclonal antibodies in this region. Furthermore, initiatives taken by government and manufacturers for increasing investment is one of the boosting factor responsible for the regional growth.
Segments
Segments Covered in the ReportThe global myasthenia gravis treatment market has been segmented on the basis of
Treatments
- Medication
- Surgery
- Others
- Hospitals
- Clinics
- Others
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Alexion Pharmaceutical Inc.
- Grifols SA
- Avadel Pharmaceuticals plc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Bausch Health Companies Inc.
- Shire plc.
Competitive Landscape
Key players competing in the myasthenia gravis treatment market are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc., Novartis AG, Pfizer Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., Bausch Health Companies Inc., and Shire plc.
Many key players are launching new products and constant innovation are driving the market growth. For instance, Argenx, in June 2020, introduced its awareness efforts for autoimmune disease myasthenia gravis. Also, major market players implement several other business strategies such as mergers, acquisitions, partnerships, collaborations, and capacity expansion to enhance their market shares.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myasthenia Gravis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Myasthenia Gravis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Myasthenia Gravis Treatment Market - Supply Chain
4.5. Global Myasthenia Gravis Treatment Market Forecast
4.5.1. Myasthenia Gravis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Myasthenia Gravis Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Myasthenia Gravis Treatment Market Absolute $ Opportunity
5. Global Myasthenia Gravis Treatment Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
5.3.1. Hospitals Clinics Others
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Myasthenia Gravis Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
7. North America Myasthenia Gravis Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
7.4.1. Hospitals Clinics Others
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
8. Latin America Myasthenia Gravis Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
8.4.1. Hospitals Clinics Others
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
9. Europe Myasthenia Gravis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
9.4.1. Hospitals Clinics Others
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Myasthenia Gravis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
10.4.1. Hospitals Clinics Others
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Myasthenia Gravis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
11.4.1. Hospitals Clinics Others
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Myasthenia Gravis Treatment Market: Market Share Analysis
12.2. Myasthenia Gravis Treatment Distributors and Customers
12.3. Myasthenia Gravis Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Alexion Pharmaceutical Inc. Grifols SA Avadel Pharmaceuticals plc. Novartis AG Pfizer Inc. AbbVie Inc.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Myasthenia Gravis Treatment Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Myasthenia Gravis Treatment Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Myasthenia Gravis Treatment Market - Supply Chain
4.5. Global Myasthenia Gravis Treatment Market Forecast
4.5.1. Myasthenia Gravis Treatment Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Myasthenia Gravis Treatment Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Myasthenia Gravis Treatment Market Absolute $ Opportunity
5. Global Myasthenia Gravis Treatment Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
5.3.1. Hospitals Clinics Others
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Myasthenia Gravis Treatment Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Myasthenia Gravis Treatment Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
7. North America Myasthenia Gravis Treatment Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
7.4.1. Hospitals Clinics Others
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
8. Latin America Myasthenia Gravis Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
8.4.1. Hospitals Clinics Others
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
9. Europe Myasthenia Gravis Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
9.4.1. Hospitals Clinics Others
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
10. Asia Pacific Myasthenia Gravis Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
10.4.1. Hospitals Clinics Others
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
11. Middle East & Africa Myasthenia Gravis Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Myasthenia Gravis Treatment Market Size and Volume Forecast by End Users
11.4.1. Hospitals Clinics Others
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Myasthenia Gravis Treatment Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Myasthenia Gravis Treatment Market: Market Share Analysis
12.2. Myasthenia Gravis Treatment Distributors and Customers
12.3. Myasthenia Gravis Treatment Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Alexion Pharmaceutical Inc. Grifols SA Avadel Pharmaceuticals plc. Novartis AG Pfizer Inc. AbbVie Inc.
Our Clients
Related Reports
Some other reports from this category!
